First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma

Discussing ASH Abstract 290: A Phase 1 Study of Talquetamab

Dr. Ajai Chari presents findings from the phase 1 study of talquetamab  for the treatment of relapsed/refractory myeloma at ASH 2020. 

What is the purpose of this study?

Talquetamab is a first-in-class, and the only investigational bispecific antibody that targets both GPRC5D, a novel multiple myeloma target, and CD3 on T-cells. 

In this video:

Dr. Ajai Chari discusses findings from a phase I study of the novel agent talquetamab, a first-in-class bispecific antibody that binds to GPRC5D and CD3, for the treatment of relapsed/refractory multiple myeloma.


Initial results for both the subcutaneous (SC) and intravenous (IV) formulations show encouraging clinical activity against the GPRC5D target, which is highly expressed on multiple myeloma cells and associated with poor prognostic factors.

ASH 2020: Abstract 290

Ajai Chari, MD 

Dr. Ajai Chari is an Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office in New York. His main areas of focus are plasma cell disorders including multiple myeloma, AL amyloidosis, POEMS syndrome, plasmacytoma, and monoclonal gammopathies of undetermined significance (MGUS). View Dr. Ajai Chari’s full biography here.


ASH 2020
IMF TV Blog Category

Source URL: